Production (Stage)
Cue Biopharma, Inc.
CUE
$0.602
-$0.0337-5.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 421.00K | 1.58M | 3.34M | 2.66M | 1.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 421.00K | 1.58M | 3.34M | 2.66M | 1.72M |
| Cost of Revenue | 7.65M | 9.78M | 8.48M | 9.53M | 9.30M |
| Gross Profit | -7.23M | -8.21M | -5.15M | -6.87M | -7.58M |
| SG&A Expenses | 5.07M | 1.42M | 3.77M | 3.51M | 5.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.72M | 11.21M | 12.25M | 13.04M | 14.39M |
| Operating Income | -12.30M | -9.63M | -8.91M | -10.38M | -12.67M |
| Income Before Tax | -12.26M | -9.50M | -8.66M | -10.17M | -12.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.26M | -9.50M | -8.66M | -10.17M | -12.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.26M | -9.50M | -8.66M | -10.17M | -12.35M |
| EBIT | -12.30M | -9.63M | -8.91M | -10.38M | -12.67M |
| EBITDA | -12.20M | -9.53M | -8.81M | -10.28M | -12.57M |
| EPS Basic | -0.17 | -0.13 | -0.17 | -0.20 | -0.25 |
| Normalized Basic EPS | -0.10 | -0.08 | -0.11 | -0.13 | -0.16 |
| EPS Diluted | -0.17 | -0.13 | -0.17 | -0.20 | -0.25 |
| Normalized Diluted EPS | -0.10 | -0.08 | -0.11 | -0.13 | -0.16 |
| Average Basic Shares Outstanding | 74.25M | 74.24M | 51.23M | 50.17M | 49.47M |
| Average Diluted Shares Outstanding | 74.25M | 74.24M | 51.23M | 50.17M | 49.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |